FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282930002> ?p ?o ?g. }

• W4282930002 endingPage "3785" @default.
• W4282930002 startingPage "3785" @default.
• W4282930002 abstract "Abstract Acute myeloid Leukemia (AML) is an aggressive hematologic malignancy with poor prognosis. Despite chromosomal and genetic heterogeneity, AML are uniformly characterized by increased reliance on oxidative phosphorylation (OXPHOS). This key metabolic hallmark of leukemia was recently reported as a feature of resistance to Cytarabine (AraC)-based therapy. Also, an aggressive phenotype and poor response to chemotherapy is associated with increased levels of Bcl-2. Despite the introduction of the Bcl-2 inhibitor venetoclax (VEN), the overall survival, particularly in older patients, remains poor. Thus, approaches to improve the sensitivity of leukemic cells to AraC-based or Bcl-2 based therapies are urgently needed.Here, we investigated the preclinical activity of ME-344, a novel isoflavone OXPHOS inhibitor, on AML cell lines and relapsed/refractory (R/R) patient samples in vitro and examined the efficacy of ME-344 in combination with VEN in Ara-C sensitive and resistant AML cell lines and patient-derived xenografts (PDX) both in vitro and in vivo.ME-344 (0-300 nM, 24 hr) significantly reduced viability of AML cell lines with EC50 of 75-100 nM and R/R AML patient samples with EC50 of 200-300 nM respectively. The cytotoxic response in AML was enhanced when ME-344 was combined with VEN, producing strong synergistic viability reduction and induction of apoptosis, as evidenced by Annexin V assay and an increased level of cleaved caspase 3 and PARP (immunoblotting). The dual inhibition of OXPHOS/Bcl-2 reduced Mcl-1 levels and showed efficacy in Mcl-1 overexpressingand Ara-C resistant AML models.Functional metabolic characterization of AML by transcriptomics and mass spectrometry demonstrated that ME-344 effectively inhibited biosynthetic pathways of nucleotides uncovering the purine biosynthesis pathway as crucial for therapeutic efficacy. ME-344 induced a dose-dependent decrease in the oxygen consumption rate (by Seahorse assay), in both AraC-sensitive and -resistant AML cell lines, and in R/R AML patient samples, which was further significantly potentiated by combination with VEN.Finally, in an aggressive AML xenograft model, ME-344 (200 mpk, i.v.) combined with subtherapeutic doses of VEN (25 mpk) reduced circulating leukemia burden and extended survival. Ongoing in vivo studies in AML PDX models will address the impact of ME-344 in the context of acquired AraC- and Bcl-2- resistance. In summary, our findings indicate ME-344 alone or in combination with Bcl-2 inhibition constitutes an important therapeutic modality that targets a unique metabolic vulnerability of AML. Citation Format: Katie H. Hurrish, Yongwei Su, Shraddha Patel, Sandra E. Wiley, Zhanjun Hou, Jenna Carter, Hasini Kalpage, Maik Hüttemann, Connie Weng, Holly Edwards, Lisa Polin, Jing Li, Jay Yang, Larry H. Matherly, Sergej Naumovich Konoplev, Jeffrey W. Taub, Marina Konopleva, Yubin Ge, Natalia Baran. ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3785." @default.
• W4282930002 created "2022-06-16" @default.
• W4282930002 creator A5008374158 @default.
• W4282930002 creator A5008376966 @default.
• W4282930002 creator A5010440853 @default.
• W4282930002 creator A5017584174 @default.
• W4282930002 creator A5018071939 @default.
• W4282930002 creator A5027520603 @default.
• W4282930002 creator A5037353971 @default.
• W4282930002 creator A5040504042 @default.
• W4282930002 creator A5043947276 @default.
• W4282930002 creator A5048054959 @default.
• W4282930002 creator A5050425961 @default.
• W4282930002 creator A5056266405 @default.
• W4282930002 creator A5058898565 @default.
• W4282930002 creator A5059091760 @default.
• W4282930002 creator A5061036650 @default.
• W4282930002 creator A5066746739 @default.
• W4282930002 creator A5081702993 @default.
• W4282930002 creator A5084102458 @default.
• W4282930002 creator A5087027288 @default.
• W4282930002 date "2022-06-15" @default.
• W4282930002 modified "2023-10-07" @default.
• W4282930002 title "Abstract 3785: ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML" @default.
• W4282930002 doi "https://doi.org/10.1158/1538-7445.am2022-3785" @default.
• W4282930002 hasPublicationYear "2022" @default.
• W4282930002 type Work @default.
• W4282930002 citedByCount "0" @default.
• W4282930002 crossrefType "journal-article" @default.
• W4282930002 hasAuthorship W4282930002A5008374158 @default.
• W4282930002 hasAuthorship W4282930002A5008376966 @default.
• W4282930002 hasAuthorship W4282930002A5010440853 @default.
• W4282930002 hasAuthorship W4282930002A5017584174 @default.
• W4282930002 hasAuthorship W4282930002A5018071939 @default.
• W4282930002 hasAuthorship W4282930002A5027520603 @default.
• W4282930002 hasAuthorship W4282930002A5037353971 @default.
• W4282930002 hasAuthorship W4282930002A5040504042 @default.
• W4282930002 hasAuthorship W4282930002A5043947276 @default.
• W4282930002 hasAuthorship W4282930002A5048054959 @default.
• W4282930002 hasAuthorship W4282930002A5050425961 @default.
• W4282930002 hasAuthorship W4282930002A5056266405 @default.
• W4282930002 hasAuthorship W4282930002A5058898565 @default.
• W4282930002 hasAuthorship W4282930002A5059091760 @default.
• W4282930002 hasAuthorship W4282930002A5061036650 @default.
• W4282930002 hasAuthorship W4282930002A5066746739 @default.
• W4282930002 hasAuthorship W4282930002A5081702993 @default.
• W4282930002 hasAuthorship W4282930002A5084102458 @default.
• W4282930002 hasAuthorship W4282930002A5087027288 @default.
• W4282930002 hasConcept C126322002 @default.
• W4282930002 hasConcept C190283241 @default.
• W4282930002 hasConcept C2777938653 @default.
• W4282930002 hasConcept C2778041864 @default.
• W4282930002 hasConcept C2778461978 @default.
• W4282930002 hasConcept C2778729363 @default.
• W4282930002 hasConcept C2779675984 @default.
• W4282930002 hasConcept C502942594 @default.
• W4282930002 hasConcept C53227056 @default.
• W4282930002 hasConcept C55493867 @default.
• W4282930002 hasConcept C71924100 @default.
• W4282930002 hasConcept C86803240 @default.
• W4282930002 hasConcept C98274493 @default.
• W4282930002 hasConceptScore W4282930002C126322002 @default.
• W4282930002 hasConceptScore W4282930002C190283241 @default.
• W4282930002 hasConceptScore W4282930002C2777938653 @default.
• W4282930002 hasConceptScore W4282930002C2778041864 @default.
• W4282930002 hasConceptScore W4282930002C2778461978 @default.
• W4282930002 hasConceptScore W4282930002C2778729363 @default.
• W4282930002 hasConceptScore W4282930002C2779675984 @default.
• W4282930002 hasConceptScore W4282930002C502942594 @default.
• W4282930002 hasConceptScore W4282930002C53227056 @default.
• W4282930002 hasConceptScore W4282930002C55493867 @default.
• W4282930002 hasConceptScore W4282930002C71924100 @default.
• W4282930002 hasConceptScore W4282930002C86803240 @default.
• W4282930002 hasConceptScore W4282930002C98274493 @default.
• W4282930002 hasIssue "12_Supplement" @default.
• W4282930002 hasLocation W42829300021 @default.
• W4282930002 hasOpenAccess W4282930002 @default.
• W4282930002 hasPrimaryLocation W42829300021 @default.
• W4282930002 hasRelatedWork W1993422021 @default.
• W4282930002 hasRelatedWork W2269392306 @default.
• W4282930002 hasRelatedWork W2357037178 @default.
• W4282930002 hasRelatedWork W2364732766 @default.
• W4282930002 hasRelatedWork W2781637722 @default.
• W4282930002 hasRelatedWork W2969404813 @default.
• W4282930002 hasRelatedWork W2990397977 @default.
• W4282930002 hasRelatedWork W3146464165 @default.
• W4282930002 hasRelatedWork W4321487956 @default.
• W4282930002 hasRelatedWork W4328012208 @default.
• W4282930002 hasVolume "82" @default.
• W4282930002 isParatext "false" @default.
• W4282930002 isRetracted "false" @default.
• W4282930002 workType "article" @default.